Methods of predicting therpeutic response in atopic dermatitis to IL-31 antagonists
First Claim
Patent Images
1. A method of treating atopic dermatits skin comprising administering an antagonist molecule to a mammal with the atopic dermatitis skin wherein the skin is characterized by cutaneous lymphocyte antigen positive T cells and the antagonist molecule specifically binds to the polypeptide comprising the amino acid sequence as shown in SEQ ID NO:
- 2 or SEQ ID NO;
4, and whereby administration of the antagonist molecule improves, prevents, inhibits or reduces the diseased skin.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.
81 Citations
17 Claims
-
1. A method of treating atopic dermatits skin comprising administering an antagonist molecule to a mammal with the atopic dermatitis skin wherein the skin is characterized by cutaneous lymphocyte antigen positive T cells and the antagonist molecule specifically binds to the polypeptide comprising the amino acid sequence as shown in SEQ ID NO:
- 2 or SEQ ID NO;
4, and whereby administration of the antagonist molecule improves, prevents, inhibits or reduces the diseased skin. - View Dependent Claims (2, 3, 4, 5)
- 2 or SEQ ID NO;
-
6. A method for treating pruritis from atopic dermatitis comprising administering an antagonist molecule to a mammal with the pruritis wherein the pruritis is characterized by cutaneous lymphocyte antigen positive T cells and wherein the antagonist molecule specifically binds to the polypeptide having the amino acid sequence as shown in SEQ ID NO:
- 2 or in SEQ ID NO;
4, and whereby administration of the antagonist molecule improves, prevents, inhibits or reduces the pruritis. - View Dependent Claims (7, 8, 9)
- 2 or in SEQ ID NO;
- 10. A method for predicting therapeutic response to an IL-31 antagonist in an individual with atopic dermatitis in need of IL-31 antagonist therapy comprising obtaining a biological sample from the patient, isolating circulating cutaneous lymphocyte positive T cells from the biological sample, and detecting IL-31 production from the isolated cutaneous lymphocyte positive T cells.
Specification